Title |
Current Limitations of Murine Models in Oncology for Ascorbate Research
|
---|---|
Published in |
Frontiers in oncology, October 2014
|
DOI | 10.3389/fonc.2014.00282 |
Pubmed ID | |
Authors |
Elizabeth J. Campbell, Gabi U. Dachs |
Abstract |
The role of vitamin C (ascorbate) in cancer prevention, tumor growth, and treatment is of intense public interest. Clinical trial data have been sparse, contradictory, and highly controversial, and robust pre-clinical data are required for progress. This paper reviews pre-clinical models and their limitations with respect to ascorbate research. Most studies have utilized animals able to synthesize ascorbate and thus are not ideal models of the human condition. More recently, genetically modified mouse models have become available; yet, all studies compared healthy and scorbutic mice. The majority of investigations to date concluded that increased ascorbate led to decreased tumor growth, but data on mechanisms and doses are inconclusive. Clinically relevant animal studies are still required to convince a generally sceptical medical audience of the potential worth of ascorbate as an adjunct to therapy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 1 | 3% |
Unknown | 28 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 6 | 21% |
Researcher | 6 | 21% |
Student > Bachelor | 3 | 10% |
Other | 2 | 7% |
Student > Postgraduate | 2 | 7% |
Other | 6 | 21% |
Unknown | 4 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 8 | 28% |
Medicine and Dentistry | 7 | 24% |
Biochemistry, Genetics and Molecular Biology | 4 | 14% |
Chemistry | 3 | 10% |
Nursing and Health Professions | 1 | 3% |
Other | 1 | 3% |
Unknown | 5 | 17% |